Breast Carcinoma
We recommend
Adjuvant Treatment of Early Invasive HER2+ Breast Cancer − Results of the Katherine Study
Women with breast cancer found to have residual invasive disease during surgery after neoadjuvant chemotherapy and HER2-targeted therapy have a significantly worse prognosis. For these patients, the Czech Oncology Society ČLS JEP recommends adjuvant therapy with trastuzumab emtansine based on data from the Katherine clinical study. However, this treatment has not yet been covered by public health insurance, with reimbursement starting from March 1, 2021.
San Antonio: Results of Breast Cancer Treatment with Combination of Pertuzumab, Trastuzumab, and AI After 6 Years
The virtual conference dedicated to breast cancer, which took place December 8–11 in San Antonio,…
Targeted Treatment of HER2-Positive Breast Tumors – Updates from ESMO 2020 Congress
The recent European Society for Medical Oncology (ESMO) Congress took place virtually. We bring you…
Articles on this topic
Is Six Months of Adjuvant Targeted Therapy Sufficient for Early Breast Cancer?
The inclusion of adjuvant targeted therapy with chemotherapy for early HER2-positive breast…
Targeted Treatment of Metastatic Breast Cancer in the 2nd Line – Experiences from Practice
The recommended treatment for metastatic HER2-positive breast cancer in the 1st line involves…
Chemoimmunotherapy in the Treatment of Breast Cancer − Final Results of the IMpassion130 Study
According to international recommendations, treatment with the immune checkpoint inhibitor…
Fixed Combination of Trastuzumab and Pertuzumab for Subcutaneous Administration in Patients with Early Breast Cancer
At a symposium focused on breast cancer, held in December 2019 in San Antonio, Texas,…
Preserving Quality of Life for Patients During Palliative Treatment of Triple-Negative Breast Cancer
An analysis of the quality of life of patients treated with a combination of atezolizumab with…
Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer
The KATHERINE clinical trial demonstrated that adjuvant therapy with trastuzumab emtansine…
Pertuzumab significantly extends the life of patients with metastatic breast cancer
The final results of the CLEOPATRA clinical trial show that patients with HER2-positive…
6 Years Follow-Up of Patients with Breast Cancer in the APHINITY Study
The primary analysis of results from the APHINITY clinical trial supported the combined…
Kadcyla in a New Indication – Adjuvant Therapy for Early HER2+ Breast Cancer
In December, the European Commission approved the expansion of the indication for Roche's…
Journal articles Fertility preserving methods in women with breast cancer before gonadotoxic therapy
Subscribe
Most read on this topic
Related topic
Most read on this topic
- Kadcyla in a New Indication – Adjuvant Therapy for Early HER2+ Breast Cancer
- Targeted Treatment of HER2-Positive Breast Tumors – Updates from ESMO 2020 Congress
- Adjuvant Treatment of Early Invasive HER2+ Breast Cancer − Results of the Katherine Study
- Preserving Quality of Life for Patients During Palliative Treatment of Triple-Negative Breast Cancer
- Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer
- Fertility preserving methods in women with breast cancer before gonadotoxic therapy
Related topic